Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan

Kun Ming Rau, Fu Ou-Yang, Ta Chung Chao, Yao Lung Kuo, Tsui Fen Cheng, Tsu Yi Chao, Dar Ren Chen, Yen Dun Tzeng, Being Whey Wang, Chun Yu Liu, Ming-Hung Hu, Yin Che Lu, Wei Jen Ou, Chin Ho Kuo, Chieh Han Chuang, Jung Yu Kan, Fang Ming Chen, Ming Feng Hou

研究成果: 雜誌貢獻文章同行評審

9 引文 斯高帕斯(Scopus)

摘要

Purpose: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. Methods: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. Results: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. Conclusions: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.

原文英語
頁(從 - 到)583-591
頁數9
期刊Breast Cancer Research and Treatment
170
發行號3
DOIs
出版狀態已發佈 - 8月 1 2018

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan」主題。共同形成了獨特的指紋。

引用此